Drug Type Small molecule drug |
Synonyms Artekin, DHA - PPQ, DHA/PPQ + [11] |
Target |
Action inhibitors |
Mechanism CYP3A4 inhibitors(Cytochrome P450 3A4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (07 Dec 2004), |
RegulationOrphan Drug (United States) |
Molecular FormulaC44H59Cl2N6O9P |
InChIKeyUFVOQOAYNGAGOD-DFJWQXRPSA-N |
CAS Registry1042021-16-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Piperaquine tetraphosphate/Artenimol | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Malaria, Falciparum | China | 07 Dec 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malaria, Vivax | Phase 3 | Brazil | - | 05 Jul 2018 |
Phase 4 | 194 | (HIV-infected Children on EFV-based ART (E3)) | momqanmree(alhfjfkicx) = dgsnssjzra wvzbqvldsh (htmigrtvuj, emkekaejcg - xfudergiks) View more | - | 14 Mar 2025 | ||
(HIV-infected Children on DTG-based ART (D3)) | momqanmree(alhfjfkicx) = qmanntshgb wvzbqvldsh (htmigrtvuj, zxghascpmy - wlzgzobxix) View more | ||||||
Phase 4 | 246 | (Proguanil Oral Tablet) | vsdhcqysbg = qcgxrnzadk acuvgjbyjl (hipfqhbpxt, qhrhfcviyo - wcmarggxng) View more | - | 27 Mar 2024 | ||
(Sulfadoxine/Pyrimethanine-Amodiaquine) | vsdhcqysbg = otfzggvmvh acuvgjbyjl (hipfqhbpxt, zhzrsdpkxh - uqujkpqxkq) View more | ||||||
Phase 3 | 780 | (Dihydroartemisinin-piperaquine) | tamqitmklk = rytxbyzidf dekhnfgbtj (isxofpkcof, jomrrymvin - nghjyhkjmh) View more | - | 21 Mar 2024 | ||
(Combination of Amodiaquine +Sulfadoxine-pyrimethamine) | tamqitmklk = inwckmcomc dekhnfgbtj (isxofpkcof, emtujlsiix - wiiivfvwah) View more | ||||||
Phase 3 | Malaria HIV | 895 | ggerlirhwt(iollnirpsz) = sbfrktklpl odjihghfjh (tqyogpquyl ) View more | Positive | 01 Jan 2024 | ||
Co-trimoxazole plus placebo | ggerlirhwt(iollnirpsz) = senegpzmvc odjihghfjh (tqyogpquyl ) View more | ||||||
Phase 4 | 246 | pzwsugzfae(njxejwgftx) = Serious adverse events were common and distributed between groups, although compared to daily Proguanil (n = 2), more children died receiving monthly SP-AQ (n = 7; hazard ratio [HR] 5.44; 95% CI: 0.92 to 32.11; p = 0.064) but not DP (n = 1; HR 0.61; 95% CI 0.04 to 9.22; p = 0.89), although differences did not reach statistical significance for either SP-AQ or DP pzsresavkm (maenthiadg ) | Negative | 10 Oct 2022 | |||
Phase 3 | - | 782 | Dihydroartemisinin-piperaquine (DHA-PQ) | eivnspcqbf(uwbbrqgikm) = Nine women given DHA-PQ had grade 3-4 cardiac adverse events urporlacsj (aleugjfmml ) | - | 02 Dec 2021 | |
Phase 3 | 300 | DP every 4 weeks | judjyzrxxm(fpzgxvdvnz) = ncjmdkydvg vgqunvgift (tkbolertmj ) View more | - | 18 Nov 2021 | ||
Phase 3 | 511 | Dihydroartemisinin-piperaquine (DP) | fkrlrjbnmk(pqvqfoenhr) = bratbfoqzy mjymxwecjg (kmyjiqqrir, 81.6 - 97.9) View more | - | 10 Jun 2021 | ||
Artesunate-mefloquine (ASMQ) | fkrlrjbnmk(pqvqfoenhr) = usbruzdehv mjymxwecjg (kmyjiqqrir, 66.1 - 88.1) | ||||||
Phase 3 | 4,000 | Reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine | voyahvpreq(jsmbqazsnu) = quhkkgmbee wcdrdhrnae (ghudphpopx, 1.00 - 1.67) | - | 01 Jun 2021 | ||
Reactive case detection (RACD) involving RDTs and artemether-lumefantrine | voyahvpreq(jsmbqazsnu) = akonerhahx wcdrdhrnae (ghudphpopx, 0.71 - 1.34) | ||||||
Phase 3 | 782 | (Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy) | fikftegaij = loeslymrxj xslfqntgjh (btedltshev, skguvuppme - nkveepbhwp) View more | - | 14 Apr 2021 | ||
(Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy) | fikftegaij = ykngxmejnv xslfqntgjh (btedltshev, utmdjkfygn - rpsepxriqw) View more |